GlaxoSmithKline isn't the only company cheering the launch of a late-stage program for a shingles vaccine that could prove to be a blockbuster. Antigenics flagged its own role in the parade and was rewarded with a 20 percent spike in its share price. Antigenics supplied the adjuvant for GSK's vaccine. And as CEO Garo Armen notes in a release, the Lexington, MA-based company stands to gain a fresh revenue stream in the event the Phase III program ends on a bright note. Report